apheresis volume failed to reach this goal after two days of apheresis. All recipients engrafted. The median time to neutrophil engraftment was 13 days (range 11 -22 days), and median time to platelet engraftment >50K was 24 days (range 15 -106). 14/18 (78%) recipients had 100% donor chimerism at day 30 post transplant. Of the 14 evaluable recipients receiving mobilized products from donors mobilized with 5mcg/kg GM-CSF+plerixafor, the incidence of grades IIeIV and III-IV acute GvHD was 35.7% and 21.2%. Of all evaluable recipients (n¼18) treated on study, the incidence of grades II-IV and III-IV acute GvHD were 44% and 22.2%. The incidence of cGvHD for all recipients surviving past 100 days (n ¼ 13) was 61.5%. CMV viremia occurred in 10/15 (66.6%) of recipients and CMV disease was identified or suspected in 5/15 (33.3%). GM-CSF at 5mcg/kg combined with IV plerixafor is a feasible combination to overcome low apheresis CD34 yields observed with either agent alone. Phenotypic and functional studies of cellular graft content are ongoing. Background: Idiopathic pneumonia syndrome (IPS) is diagnosed by clinical/radiographic presentation and the exclusion of infection. However, molecular diagnostic methods may allow cases previously classified as idiopathic to be linked to an infectious agent. We applied a broad panel of currently available molecular tests and pathogen discovery methods to patients with IPS and correlated pathogen detection with outcome. Methods: Frozen bronchoalveolar lavage (BAL) samples from 69 HCT patients with IPS diagnosed from 1992 to 2006 were tested by Q-PCR for Legionella, M. pneumoniae, C. pneumoniae, HSV, VZV, EBV, CMV, HHV-6, polyomavirus (BK, JC, WU, KI), parvovirus B19, RSV, PIV, Influenza, HMPV, ADV, HRV, CoVs, HBoV, Enterovirus and Parechovirus, and for aspergillus GM (aGM). Research BALs obtained between day 35 and 50 from 21 asymptomatic HCT patients served as controls. Pathogens were categorized by quantity and known/unknown pathogenicity; the association with overall mortality was analyzed using Cox regression models. Results: Among 69 HCT patients with IPS (time from HCT to BAL: median 22 days, range 4e119), 39 (57%) had a pathogen detected, compared to 11 out of 21 controls (52%); high pathogen load was detected in 19% and 5%, respectively (Table) . The most frequent pathogens were HHV-6 and HRV; CMV low-level shedding was also detected. Among the patients with IPS, the presence of a pathogen was associated with higher mortality in multivariate models (HR, 1.92; p¼0.03; adjusted for donor type, steroid use, and diffuse alveolar hemorrhage); neither pathogenicity category (Figure) nor pathogen load were significantly associated with mortality. Conclusions: A significant number of pathogens were detected in patients with IPS, and pathogen detection was associated with increased mortality. The increased mortality could be due to lack of specific treatment and/or use of corticosteroids. Known pathogens (aspergillus, RSV, PIV, HMPV) can now be readily detected by multiplex PCR and the aGM assay. The interpretation of the detection of pathogens of unknown significance (HHV-6, HRV) is more difficult, but mortality was similar to that of known pathogens. Overall, our data suggest that expanded infection detection panels may re-classify a significant number of IPS cases as infectious pneumonia. The values indicate the total number of patients (percentage of detected patients). * High load: >100,000 copies/ml, <32 cycle threshold (HRV) or co-detection of a GM in serum. 
